On Tuesday, KalVista Pharmaceuticals Inc (NASDAQ: KALV) opened higher 3.67% from the last session, before settling in for the closing price of $11.99. Price fluctuations for KALV have ranged from $7.30 to $15.50 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has dropped its sales by -24.26% annually for the last half of the decade. Company’s average yearly earnings per share was noted 2.47% at the time writing. With a float of $38.34 million, this company’s outstanding shares have now reached $43.27 million.
In an organization with 150 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 46.1%, operating margin of -14231.51%, and the pretax margin is -12967.58%.
KalVista Pharmaceuticals Inc (KALV) Insider Updates
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of KalVista Pharmaceuticals Inc is 22.42%, while institutional ownership is 89.26%. The most recent insider transaction that took place on Mar 07 ’25, was worth 79,828. In this transaction CHIEF EXECUTIVE OFFICER of this company sold 6,669 shares at a rate of $11.97, taking the stock ownership to the 287,811 shares. Before that another transaction happened on Feb 24 ’25, when Company’s CHIEF MEDICAL OFFICER sold 2,394 for $10.02, making the entire transaction worth $23,988. This insider now owns 102,940 shares in total.
KalVista Pharmaceuticals Inc (KALV) Performance Highlights and Predictions
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.91 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 2.47% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 29.77% during the next five years compared to -20.06% drop over the previous five years of trading.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Trading Performance Indicators
Check out the current performance indicators for KalVista Pharmaceuticals Inc (KALV). In the past quarter, the stock posted a quick ratio of 6.87.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.64, a number that is poised to hit -0.87 in the next quarter and is forecasted to reach -2.53 in one year’s time.
Technical Analysis of KalVista Pharmaceuticals Inc (KALV)
Let’s dig in a bit further. During the last 5-days, its volume was 0.67 million. That was better than the volume of 0.43 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 87.13%. Additionally, its Average True Range was 0.67.
During the past 100 days, KalVista Pharmaceuticals Inc’s (KALV) raw stochastic average was set at 92.43%, which indicates a significant increase from 91.20% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 52.72% in the past 14 days, which was lower than the 57.68% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $9.52, while its 200-day Moving Average is $11.07. However, in the short run, KalVista Pharmaceuticals Inc’s stock first resistance to watch stands at $12.81. Second resistance stands at $13.20. The third major resistance level sits at $13.72. If the price goes on to break the first support level at $11.90, it is likely to go to the next support level at $11.38. Assuming the price breaks the second support level, the third support level stands at $10.99.
KalVista Pharmaceuticals Inc (NASDAQ: KALV) Key Stats
There are currently 49,418K shares outstanding in the company with a market cap of 614.27 million. Presently, the company’s annual sales total 0 K according to its annual income of -126,640 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -42,270 K.
